CRISPR Therapeutics Option Alert: Nov 21 $72 Puts at the Bid: 1250 vs 0 OI; Earnings 11/4 Before Open [est] 

CRISPR Therapeutics Option Alert: Nov 21 $72 Puts at the Bid: 1250 @ $6.2 vs 0 OI; Earnings 11/4 Before Open [est] Ref=$72.555

CRISPR Therapeutics

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

CRISPR Therapeutics AG

Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth

Small Cap

Opinion

Press Releases

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Earnings

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

News

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

Health Care

General

CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Australia's Largest University Establishes 'Monash Boston Hub' to Accelerate Global Biotech Partnerships and Licensing

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

ADIA

AVAI

BNTX

CLDI

CRSP

CTMX

FATE

IBRX

MESO

VRTX

Abivax

Arcellx

Akero Therapeutics

Alkermes

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BridgeBio Pharma

Caris Life Sciences

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Jyong Biotech

Merus

Metsera

Nuvalent

Vaxcyte

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Avidity Biosciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

TG Therapeutics

B of A Securities

Needham

HC Wainwright & Co.

JP Morgan

Comments

CRISPR Therapeutics

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL